[Alitretinoin: Toctino].
Berbis
P
P
Service de dermatologie, hôpital Nord, Assistance publique-Hôpitaux de Marseille, université de la Méditerranée Aix-Marseille II, chemin des Bourrellys, 13015 Marseille, France. philippe.berbis@ap-hm.fr
D000014:Abnormalities, Drug-Induced / Q000209:etiology; D000328:Adult; D000077556:Alitretinoin; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002214:Capsules; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003267:Contraception; D000075202:Contraindications; D004333:Drug Administration Routes; D016527:Drug Costs; D004485:Eczema / Q000188:drug therapy; D005260:Female; D005602:France; D006261:Headache / Q000139:chemically induced; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced; D007155:Immunologic Factors / Q000627:therapeutic use; D008297:Male; D011247:Pregnancy; D047488:Retinoid X Receptors / Q000819:agonists; D012943:Social Security; D014212:Tretinoin / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D002214:Capsules; D007155:Immunologic Factors; D047488:Retinoid X Receptors; D000077556:Alitretinoin; D014212:Tretinoin